Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	POH
Latest Price:	0.20 (2.56% )
52-week High:	0.21
52-week Low:	0.10
Market Cap:	164.72M

1 year chart

1 day chart

Phosphagenics Limited

Phosphagenics (ASX: POH) is a Melbourne-based biotechnology company. Its core technology is built around the science and application of TPM™ delivery systems. This system enables transdermal delivery of proven pharmaceutical actives and enhances dermal delivery of pharmaceutical, cosmeceutical and nutraceutical actives.

Phosphagenics TPM delivery technology used by Le Métier de Beauté in US personal care product launch

Wednesday, November 04, 2009

Melbourne biotechnology company Phosphagenics (ASX: POH; OTCQX: PPGNY) announced today that the New York-based luxury beauty company, Le Métier de Beauté, will launch its new cosmetic treatment products, Peau de Vierge anti-aging collection, exclusively with Phosphagenics’ TPM delivery technology across the US this month.

To support the launch, Le Métier de Beauté will commence a significant marketing campaign focusing on Phosphagenics’ TPM delivery technology as the primary point of differentiation.

Phosphagenics core technology offering is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.

In July, Phosphagenics announced that Le Métier de Beauté agreed to license to manufacture and sell products using Phosphagenics’ TPM technology.

The company said its strategy (outlined at the May AGM) to quickly and at low cost to the company, to enter the highly lucrative US personal care market has been achieved.

The arrangement with Le Métier de Beauté will enable an entry into profitable personal care market, imiting the company's financial exposure and maintaining substantial financial upside.

By partnering with Le Métier de Beauté, will allow Phosphagenics to remain focused on its core pharmaceutical development business.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.